Da olopatadin primært udskilles som uændret aktiv substans i urinen, vil nedsat nyrefunktion ændre olopatadins farmakokinetik med peak plasmakoncentrationer 2, 3 gange større hos patienter med svær nedsat nyrefunktion (gennemsnit keratininclearance 13, 0 ml/ min) sammenlignet med raske voksne.
Since olopatadine is excreted in urine primarily as unchanged active substance, impairment of renal function alters the pharmacokinetics of olopatadine with peak plasma concentrations 2.3-fold greater in patients with severe renal impairment (mean creatinine clearance of 13.0 ml/ min) compared to healthy adults.